{"Symbol": "MRNA", "AssetType": "Common Stock", "Name": "Moderna Inc", "Description": "Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.", "CIK": "1682852", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "LIFE SCIENCES", "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)", "Address": "200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, US", "OfficialSite": "https://www.modernatx.com", "FiscalYearEnd": "December", "LatestQuarter": "2024-12-31", "MarketCapitalization": "9951676000", "EBITDA": "-3756000000", "PERatio": "None", "PEGRatio": "0", "BookValue": "28.24", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-9.28", "RevenuePerShareTTM": "8.43", "ProfitMargin": "-1.1", "OperatingMarginTTM": "-1.29", "ReturnOnAssetsTTM": "-0.151", "ReturnOnEquityTTM": "-0.288", "RevenueTTM": "3236000000", "GrossProfitTTM": "-2771000064", "DilutedEPSTTM": "-9.28", "QuarterlyEarningsGrowthYOY": "-0.851", "QuarterlyRevenueGrowthYOY": "-0.656", "AnalystTargetPrice": "50.92", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "5", "AnalystRatingHold": "17", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "3", "TrailingPE": "-", "ForwardPE": "32.47", "PriceToSalesRatioTTM": "3.075", "PriceToBookRatio": "0.891", "EVToRevenue": "1.075", "EVToEBITDA": "4.641", "Beta": "2.233", "52WeekHigh": "170.47", "52WeekLow": "23.15", "50DayMovingAverage": "31.07", "200DayMovingAverage": "55.96", "SharesOutstanding": "386623000", "DividendDate": "None", "ExDividendDate": "None"}